Provectus Biopharmaceuticals I - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PVCT Over the counter 2834 http://www.provectusbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Provectus Biopharmaceuticals I

PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE - Jun 19th, 2018 7:00 am
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE PV-10 ABSTRACT AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING - May 17th, 2018 6:00 am
PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA - May 7th, 2018 6:00 am
STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE - Apr 30th, 2018 7:00 am
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING - Apr 25th, 2018 2:00 pm
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS - Apr 24th, 2018 5:00 am
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY - Apr 19th, 2018 4:00 am
PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY - Apr 18th, 2018 4:00 am